• Zosuquidar (LY335979): MDR Assay Workflow

  2026-09-16

  Zosuquidar (LY335979) 3HCl provides a selective way to test whether P-glycoprotein-driven efflux is suppressing chemotherapy response. This practical guide connects cell-based sensitization, transporter assays, and pharmacokinetic controls to help researchers distinguish true MDR reversal from nonspecific cytotoxicity.

• CSBTA Pharmacokinetics in MASH: Study Insights

  2026-09-16

  The reference study shows that MASH substantially changes the exposure, liver distribution, and hepatocyte accumulation of key Corydalis saxicola Bunting total alkaloids. By combining UHPLC-MS/MS pharmacokinetics with transporter, microsomal metabolism, and PXR-related analyses, it links disease-state pharmacokinetic variability to altered CYP450, Oatp1b2, and P-glycoprotein biology.

• Norepinephrine Formulation Reporting in Critical Care

  2026-09-15

  The SCCM–ESICM position paper identifies a major reproducibility and patient-safety problem: norepinephrine doses may be labeled and reported as either the conjugated salt or norepinephrine base. Its central recommendation is to standardize reporting around norepinephrine base while clearly documenting formulation, dose calculations, and country-specific labeling.

• CX-4945: CK2, ECE-1c, and Cancer Stemness

  2026-09-15

  Explore how CX-4945 (Silmitasertib) can connect CK2 inhibition with ECE-1c stability, stemness, and chemoresistance in lung cancer models. This article emphasizes causal assay design rather than a conventional inhibitor workflow.

• Ziprasidone Augmentation in Anxious Depression

  2026-09-14

  This post-hoc moderator analysis examined whether anxious depression altered the antidepressant or anxiolytic response to ziprasidone added to escitalopram. The findings support comparable depressive symptom improvement across subgroups, while providing no clinically meaningful evidence that augmentation preferentially relieves anxiety.

• JNJ-26854165 (Serdemetan) Assay Guide

  2026-09-14

  This scenario-based guide explains how JNJ-26854165 (Serdemetan), SKU A4204, can improve interpretation of proliferation, viability, apoptosis, migration, and radiation-response assays. It connects product-specific handling data with evidence that separates growth inhibition from true cell killing.

• IgSF6, ER Stress, and Antibacterial Macrophages

  2026-09-13

  The reference study identifies endoplasmic reticulum-localized IgSF6 as a regulator of intestinal macrophage stress responses, showing that its deficiency improves antibacterial defense while increasing susceptibility to chemically induced colitis. Its genetic, infection, and pathway-inhibition experiments connect the IRE1α–XBP1 axis and reactive oxygen species to a context-dependent balance between pathogen clearance and intestinal homeostasis.

• BCA Quantification for BPD Mechanistic Research

  2026-09-12

  A translational framework for using bicinchoninic acid protein quantification to strengthen mechanistic studies of LXR signaling, cholesterol overload, and alveolar epithelial apoptosis in bronchopulmonary dysplasia.

• Ginkgo Compound Cocktail Improves Yeast Longevity

  2026-09-11

  A 2026 study combined LC–MS/MS, network pharmacology, and mitochondrial phenotyping to identify a four-compound Ginkgo biloba cocktail that improves stress resistance, mitochondrial performance, and chronological lifespan in yeast. The work supports pathway-guided combination design while showing why extract activity should not be attributed automatically to a single constituent.

• Plerixafor (AMD3100): CXCR4 Assay Design

  2026-09-11

  Plerixafor (AMD3100) is more than a CXCR4 antagonist: it is a mechanistic perturbation tool for linking receptor signaling to migration, mobilization, and tumor-microenvironment phenotypes. This guide explains how to design interpretable assays around the compound while using recent colorectal cancer evidence to sharpen experimental decisions.

• Clozapine N-oxide: Assay Design for Learning

  2026-09-10

  Clozapine N-oxide (CNO) is more than a DREADDs activator: it can help test whether patterned interneuron suppression causes durable cortical plasticity. This article translates recent SST-neuron findings into practical chemogenetic assay decisions, controls, and handling guidance.

• STING–p38 Signaling in Glaucoma Surgery Scarring

  2026-09-10

  Ye et al. identify STING as an upstream regulator of p38 MAPK-associated inflammation and fibrosis after glaucoma filtration surgery. Genetic STING deletion and pharmacological inhibition reduced inflammatory cytokines, fibroblast activation, and collagen deposition in mice, suggesting a mechanistically defined target for improving bleb durability.

• WAY-100635: Interpreting 5-HT1A Pain Assays

  2026-09-09

  WAY-100635 is a selective 5-HT1A antagonist for separating receptor binding, circuit activity, and pain-related behavior. This guide translates cannabidiol pain findings into a rigorous assay strategy while clarifying what pharmacological antagonism can—and cannot—prove.

• Kanamycin Sulfate for Reliable Cell Assays

  2026-09-09

  Learn how Kanamycin Sulfate, SKU A2516, can support controlled bacterial selection, contamination management, and interpretation of cell-based workflows. This scenario-driven guide covers compatibility, preparation, storage, data interpretation, and practical vendor-selection criteria for biomedical laboratories.

• Plerixafor (AMD3100): CXCR4 Research Guide

  2026-09-08

  Plerixafor, also called AMD3100, is a small-molecule CXCR4 antagonist used to study CXCL12 signaling, hematopoietic stem cell mobilization, cancer-cell migration, and immune-cell trafficking. Its strongest established research value is pathway perturbation, while cancer and regenerative applications remain model- and context-dependent.

8327 records 1/556 page Next 12345 下5页 Last page